The utility of value frameworks in cost communications: making them real for patients.
作者信息
Shih Ya-Chen Tina, Yabroff K Robin, Bradley Cathy
机构信息
University of California Los Angeles Jonsson Comprehensive Cancer Center and Department of Radiation Oncology, School of Medicine, Los Angeles, CA, USA.
Department of Surveillance and Health Equity Science, American Cancer Society, Atlanta, GA, USA.
出版信息
J Natl Cancer Inst. 2024 Sep 1;116(9):1411-1413. doi: 10.1093/jnci/djae156.
Abstract
摘要
相似文献
1
The utility of value frameworks in cost communications: making them real for patients.价值框架在成本沟通中的作用：让患者切实理解它们。
J Natl Cancer Inst. 2024 Sep 1;116(9):1411-1413. doi: 10.1093/jnci/djae156.
2
Understanding factors influencing the implementation of medicine risk communications by healthcare professionals in clinical practice: a systematic review using the Theoretical Domains Framework.理解影响医疗保健专业人员在临床实践中实施医学风险沟通的因素：使用理论领域框架进行的系统评价。
Res Social Adm Pharm. 2024 Feb;20(2):86-98. doi: 10.1016/j.sapharm.2023.10.004. Epub 2023 Oct 18.
3
The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology.延长生命疗法的特殊经济学：肿瘤学健康经济评估中的成本核算方法综述
Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):931-40. doi: 10.1586/14737167.2015.1102633. Epub 2015 Oct 19.
4
A systematic review of the cost and cost-effectiveness of electronic discharge communications.电子出院沟通的成本及成本效益的系统评价
BMJ Open. 2017 Jul 2;7(6):e014722. doi: 10.1136/bmjopen-2016-014722.
5
Economic aspects of chemotherapy.化疗的经济方面。
Acta Oncol. 2001;40(2-3):412-33. doi: 10.1080/02841860151116501.
6
Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.将成本效益、可负担性和资源影响因素纳入指南制定中：COPD 指南制定中整合和协调工作的第 6 条。美国胸科学会/欧洲呼吸学会官方研讨会报告。
Proc Am Thorac Soc. 2012 Dec;9(5):251-5. doi: 10.1513/pats.201208-059ST.
7
Contributing to a value-based health care framework for lung cancer patients in Switzerland - A methodological approach to merge routinely collected hospital data.为瑞士肺癌患者构建基于价值的医疗保健框架——一种整合常规收集的医院数据的方法。
PLoS One. 2025 Jul 10;20(7):e0327814. doi: 10.1371/journal.pone.0327814. eCollection 2025.
8
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.巴雷特食管的监测：通过系统评价、专家研讨会和经济模型探索不确定性
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.
9
The Application of Time-Driven Activity-Based Costing in Oncology: A Systematic Review.时间驱动作业成本法在肿瘤学中的应用：一项系统综述
Value Health. 2025 Apr;28(4):643-651. doi: 10.1016/j.jval.2024.11.003. Epub 2024 Nov 26.
10
Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.血友病疾病负担：血友病成本效益文献的系统评价。
J Manag Care Spec Pharm. 2018 Jul;24(7):632-642. doi: 10.18553/jmcp.2018.24.7.632.
本文引用的文献
1
Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.晚期非小细胞肺癌和黑色素瘤患者的医疗成本讨论：一项大型基于人群的试点研究结果。
Cancer. 2024 Oct 1;130(19):3364-3374. doi: 10.1002/cncr.35380. Epub 2024 Jun 13.
2
Association between oral targeted cancer drug net health benefit, uptake, and spending.口腔靶向抗癌药物的净健康效益、采用率和支出之间的关联。
J Natl Cancer Inst. 2024 Sep 1;116(9):1479-1486. doi: 10.1093/jnci/djae110.
3
Prescription Drug Provisions in the Inflation Reduction Act: Any Relief of Financial Hardship for Patients With Cancer?《降低通胀法案》中的处方药条款：能否缓解癌症患者的经济困境？
JAMA Oncol. 2023 Feb 1;9(2):165-167. doi: 10.1001/jamaoncol.2022.5805.
4
Growing Financial Burden From High-Cost Targeted Oral Anticancer Medicines Among Medicare Beneficiaries With Cancer.癌症 Medicare 受益人群中高成本靶向口服抗癌药物带来的日益增长的经济负担。
JCO Oncol Pract. 2022 Nov;18(11):e1739-e1749. doi: 10.1200/OP.22.00171. Epub 2022 Sep 13.
5
Costs Around the First Year of Diagnosis for 4 Common Cancers Among the Privately Insured.4 种常见癌症患者在确诊后第一年的费用。
J Natl Cancer Inst. 2022 Oct 6;114(10):1392-1399. doi: 10.1093/jnci/djac141.
6
Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.口腔肿瘤均等化法案、用药情况和血液癌症患者自付费用。
J Natl Cancer Inst. 2020 Oct 1;112(10):1055-1062. doi: 10.1093/jnci/djz243.
7
Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.州平价法实施后口服抗癌治疗患者自付费用和医疗支出变化。
JAMA Oncol. 2018 Jun 14;4(6):e173598. doi: 10.1001/jamaoncol.2017.3598.
8
Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.靶向口服抗癌药物价格上涨及其给医疗保险受益人群带来的相关经济负担。
J Clin Oncol. 2017 Aug 1;35(22):2482-2489. doi: 10.1200/JCO.2017.72.3742. Epub 2017 May 4.
9
A review of cost communication in oncology: Patient attitude, provider acceptance, and outcome assessment.肿瘤学中的成本沟通综述：患者态度、提供者接受度和结果评估。
Cancer. 2017 May 15;123(6):928-939. doi: 10.1002/cncr.30423. Epub 2016 Nov 28.
10
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.更新美国临床肿瘤学会价值框架：针对收到的评论进行的修订与思考
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.
Zotero 插件